Related Experiment Video
Updated: Sep 28, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Safety and efficacy of a new oral contraceptive containing drospirenone
1Division of Reproductive Genetics, Department of Obstetrics and Gynecology, University of Illinois at Chicago, 820 South Wood Street, M/C 808, Chicago, IL 60612-7313, USA.
Abstract:
An oral contraceptive containing ethinyl estradiol and the unique progestin drospirenone provides a new contraceptive option. Ethinyl estradiol is the form of synthetic estrogen used in most oral contraceptives. Drospirenone differs from other synthetic progestins in that it is derived from 17 alpha-spirolactone and is an analogue of spironolactone. The oral contraceptive containing ethinyl estradiol and the unique progestin drospirenone has been shown to be highly efficacious and to provide safety equivalent to that of other oral contraceptive formulations.
Related Concept Videos
Birth Control Methods
Intrauterine Drug Delivery Systems
Oral Drug Delivery Systems: Delayed-Release Systems
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Oral Drug Delivery Systems: Continuous-Release Systems
Oral Drug Delivery Systems: Introduction